Farrerol
Code | Size | Price |
---|
TAR-T6S0525-1mL | 1 mL * 10 mM (in DMSO) | £127.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6S0525-20mg | 20mg | £159.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or activates the Akt, p38 and ERK to facilitate the release of Nrf2 from Keap1 and subsequent reduces the intracellular production of reactive oxygen species via the induction of HO-1 expression. 4. Farrerol has protective effects against H2O2-induced apoptosis in EA.hy926 cells, and suggests that Farrerol is a potential candidate for the intervention of endothelial-injury-associated cardiovascular diseases.
CAS:
24211-30-1
Formula:
C17H16O5
Molecular Weight:
300.31
Pathway:
PI3K/Akt/mTOR signaling; MAPK; Cytoskeletal Signaling
Purity:
0.9996
SMILES:
Cc1c(O)c(C)c2O[C@@H](CC(=O)c2c1O)c1ccc(O)cc1
Target:
ERK; p38 MAPK; Akt
References
Liu E , Liang T , Wang X , et al. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway[J]. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP), 2015, 24(5):365.